Corient Private Wealth
RPRX icon

Corient Private Wealth’s Royalty Pharma RPRX Stock Holding History

Corient Private Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.48M Sell
116,377
-159,213
-58% -$6.97M 0.01% 984
2025
Q4 		$9.11M Buy
275,590
+153,434
+126% +$5.85M 0.01% 810
2025
Q3 		$4.31M Buy
122,156
+49,754
+69% +$1.8M 0.01% 760
2025
Q2 		$2.61M Sell
72,402
-4,510
-6% -$149K ﹤0.01% 922
2025
Q1 		$2.39M Buy
76,912
+30,663
+66% +$972K ﹤0.01% 913
2024
Q4 		$1.18M Buy
46,249
+21,383
+86% +$567K ﹤0.01% 1243
2024
Q3 		$703K Sell
24,866
-1,982
-7% -$54.9K ﹤0.01% 1569
2024
Q2 		$708K Buy
26,848
+214
+0.8% +$5.93K ﹤0.01% 1468
2024
Q1 		$809K Buy
26,634
+5,288
+25% +$156K ﹤0.01% 1388
2023
Q4 		$600K Buy
+21,346
New +$587K ﹤0.01% 1521
2023
Q2 		– Sell
-6,275
Closed -$226K – 2153
2023
Q1 		$226K Buy
+6,275
New +$233K ﹤0.01% 1743

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Corient Private Wealth's RPRX Position: Q1 2026 in Review

Corient Private Wealth reduced its Royalty Pharma (RPRX) stake by 58% in Q1 2026, selling an estimated $6.97M and leaving 116,377 shares worth $3.48M. The position accounts for 0.01% of the portfolio, ranked #984.

Corient Private Wealth first reported a position in RPRX in Q1 2023 and has held it in 11 quarters since. The position peaked at $9.11M in Q4 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Corient Private Wealth held 116,377 shares of Royalty Pharma worth $3.48M as of Q1 2026.
  • Corient Private Wealth sold 159,213 Royalty Pharma shares in Q1 2026, an estimated $6.97M.
  • Royalty Pharma made up 0.01% of Corient Private Wealth's portfolio in Q1 2026, its #984 holding.
  • Corient Private Wealth first reported a position in Royalty Pharma in Q1 2023 and has held it in 11 quarters since.
  • Corient Private Wealth's Royalty Pharma position peaked at $9.11M in Q4 2025.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.